RUA Stock Overview
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally.
RUA Life Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£1.44|
|52 Week High||UK£1.80|
|52 Week Low||UK£1.13|
|1 Month Change||-6.82%|
|3 Month Change||12.99%|
|1 Year Change||-10.31%|
|3 Year Change||187.00%|
|5 Year Change||583.33%|
|Change since IPO||-89.64%|
Recent News & Updates
The Rua Life Sciences (LON:RUA) Share Price Is Up 481% And Shareholders Are Delighted
Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies...
|RUA||GB Medical Equipment||GB Market|
Return vs Industry: RUA underperformed the UK Medical Equipment industry which returned -4.3% over the past year.
Return vs Market: RUA underperformed the UK Market which returned 17.9% over the past year.
|RUA Average Weekly Movement||6.5%|
|Medical Equipment Industry Average Movement||5.1%|
|Market Average Movement||4.8%|
|10% most volatile stocks in GB Market||9.7%|
|10% least volatile stocks in GB Market||2.5%|
Stable Share Price: RUA is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: RUA's weekly volatility (6%) has been stable over the past year.
About the Company
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves.
RUA Life Sciences Fundamentals Summary
|RUA fundamental statistics|
Is RUA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RUA income statement (TTM)|
|Cost of Revenue||UK£276.00k|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.065|
|Net Profit Margin||-94.96%|
How did RUA perform over the long term?See historical performance and comparison
Is RUA Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RUA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RUA is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.
PE vs Market: RUA is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RUA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RUA is overvalued based on its PB Ratio (3.7x) compared to the GB Medical Equipment industry average (3.5x).
How is RUA Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted Healthcare industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RUA's forecast earnings growth is above the savings rate (0.9%).
Earnings vs Market: Insufficient data to determine if RUA's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if RUA's revenue is forecast to grow faster than the UK market.
High Growth Revenue: Insufficient data to determine if RUA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RUA's Return on Equity is forecast to be high in 3 years time
How has RUA Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RUA is currently unprofitable.
Growing Profit Margin: RUA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RUA is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Accelerating Growth: Unable to compare RUA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RUA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (97.5%).
Return on Equity
High ROE: RUA has a negative Return on Equity (-17.06%), as it is currently unprofitable.
How is RUA Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: RUA's short term assets (£7.3M) exceed its short term liabilities (£1.1M).
Long Term Liabilities: RUA's short term assets (£7.3M) exceed its long term liabilities (£550.0K).
Debt to Equity History and Analysis
Debt Level: RUA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if RUA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RUA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: RUA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 53.7% each year.
What is RUA Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RUA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RUA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RUA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RUA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RUA's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
RUA Life Sciences has no CEO, or we have no data on them.
Experienced Board: RUA's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.7%.
RUA Life Sciences plc's employee growth, exchange listings and data sources
- Name: RUA Life Sciences plc
- Ticker: RUA
- Exchange: AIM
- Founded: 1996
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: UK£31.835m
- Shares outstanding: 22.18m
- Website: https://rualifesciences.com
Number of Employees
- RUA Life Sciences plc
- 2 Drummond Crescent
- Riverside Business Park
- KA11 5AN
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/26 21:11|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.